Cited by 1,878HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV, Drug Use, Sexual Risk

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Open access

McCormack, Sheena, Dunn, David T, Desai, Monica, Dolling, David I, Gafos, Mitzy, Gilson, Richard, Sullivan, Ann K, Clarke, Amanda, Reeves, Iain, Schembri, Gabriel, Mackie, Nicola, Bowman, Christine, Lacey, Charles J, Apea, Vanessa, Brady, Michael, Fox, Julie, Taylor, Stephen, Antonucci, Simone, Khoo, Saye H, Rooney, James, Nardone, Anthony, Fisher, Martin, McOwan, Alan, Phillips, Andrew N, Johnson, Anne M, Gazzard, Brian, Gill, Owen N·2016·The Lancet

DOI 10.1016/s0140-6736(15)00056-2PMC PMC4700047

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection. However, this benefit could be counteracted by risk compensation in users of PrEP. We did the PROUD study to assess this effect. METHODS: PROUD is an open-label randomised trial done at 13 sexual health clinics in England. We enrolled HIV-negative gay and other men who have sex with men who had had anal intercourse without a condom in the previous 90 days. Participants were randomly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a deferral period of 1 year. Randomisation was done via web-based access to a central computer-generated list with variable block sizes (stratified by clinical site). Follow-up was quarterly. The primary outcomes for the pilot phase were time to accrue 500 participants and retention; secondary outcomes included incident HIV infection during the deferral period, safety, adherence, and risk compensation. The trial is registered with ISRCTN (number ISRCTN94465371) and ClinicalTrials.gov (NCT02065986). FINDINGS: We enrolled 544 participants (275 in the immediate group, 269 in the deferred group) between Nov 29, 2012, and April 30, 2014. Based on early evidence of effectiveness, the trial steering committee recommended on Oct 13, 2014, that all deferred participants be offered PrEP. Follow-up for HIV incidence was complete for 243 (94%) of 259 patient-years in the immediate group versus 222 (90%) of 245 patient-years in the deferred group. Three HIV infections occurred in the immediate group (1·2/100 person-years) versus 20 in the deferred group (9·0/100 person-years) despite 174 prescriptions of post-exposure prophylaxis in the deferred group (relative reduction 86%, 90% CI 64-96, p=0·0001; absolute difference 7·8/100 person-years, 90% CI 4·3-11·3). 13 men (90% CI 9-23) in a similar population would need access to 1 year of PrEP to avert one HIV infection. We recorded no serious adverse drug reactions; 28 adverse events, most commonly nausea, headache, and arthralgia, resulted in interruption of PrEp. We detected no difference in the occurrence of sexually transmitted infections, including rectal gonorrhoea and chlamydia, between groups, despite a suggestion of risk compensation among some PrEP recipients. INTERPRETATION: In this high incidence population, daily tenofovir-emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting. There was no evidence of an increase in other sexually transmitted infections. Our findings strongly support the addition of PrEP to the standard of prevention for men who have sex with men at risk of HIV infection. FUNDING: MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)00056-2

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Trial profile *First to deferred and subsequently to immediate; considered in the deferred group for analyses but continued on pre-exposure prophylaxis. †19 pairs of partners were allocated to the same group (14 to immediate, five to deferred) including six pairs (all assigned to the immediate group) not enrolled concurrently. ‡One participant who was allocated to the deferred group was prescribed immediate pre-exposure prophylaxis in error; he was included in the deferred group for analyses but continued on pre-exposure prophylaxis. §Includes unable to contact, moved away, and non-attendance as no longer at risk. ¶HIV status ascertained if confirmed HIV-positive or HIV-negative test after 48 weeks or after Oct 13, 2014.CC BY · PubMed Central

Figure 2 Incident HIV infections Left bound for each HIV case represents last non-reactive HIV test; right bound represents first reactive HIV test. The dotted line represents time when participants in the deferred group became eligible for pre-exposure prophylaxis under the original protocol. *Had a stored enrolment sample that tested positive for HIV RNA but was retained in the analysis.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,895
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Sifting the evidence---what's wrong with significance tests? Another comment on the role of statistical methods
Sterne, J. A. C. (2001) · BMJ · doi:10.1136/bmj.322.7280.226 · Cited by 1,466
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Self-citation
Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men
Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., Guanira, J. V., McMahan, V., Bushman, L. R., Casapía, M., Montoya, O., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004006 · Cited by 1,054
Risk compensation: the Achilles' heel of innovations in HIV prevention?
Cassell, M. M., Halperin, D. T., Shelton, J. D., & Stanton, D. (2006) · BMJ · doi:10.1136/bmj.332.7541.605 · Cited by 390

Show all 24 references

Research works printed but not linked: 2

Antonucci S, Desai M, Dolling D, et al. The UK PROUD PrEP Pilot study: a baseline analysis. 20th International AIDS Conference; July 20–25, 2014; Melbourne, Australia. Abstract THPE197.
Molina J-M, Capitant C, Charreau I, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on Retroviruses and Opportunistic Infections; Feb 23–26, 2015; Seattle, WA, USA. Abstract 23LB.

Sorted by citations

Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Molina, J., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C. L., Gall, J.-M. L., Cua, É., Pasquet, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506273 · Cited by 1,698
Self-citation
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
Sexually transmitted infections: challenges ahead
Unemo, M., Bradshaw, C. S., Hocking, J. S., de Vries, H. J. C., Francis, S. C., Mabey, D. C. W., Marrazzo, J. M., Sonder, G. J. B., Schwebke, J. R., Hoornenborg, E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30310-9 · Cited by 776
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Günthard, H. F., Saag, M. S., Benson, C. A., del Rı́o, C., Eron, J. J., Gallant, J. E., Hoy, J., Mugavero, M. J., Sax, P. E., Thompson, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 740
Gonorrhoea
Unemo, M., Seifert, H. S., Hook, E. W., Hawkes, S., Ndowa, F. J., & Dillon, J. R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0128-6 · Cited by 558
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.
Bavinton, B. R., Pinto, A. N., Phanuphak, N., Grinsztejn, B., Prestage, G. P., Zablotska-Manos, I. B., Jin, F., Fairley, C. K., Moore, R., Roth, N., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30132-2 · Cited by 524
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina, J.-M., Charreau, I., Spire, B., Cotte, L., Chas, J., Capitant, C., Tremblay, C., Rojas-Castro, D., Cua, E., Pasquet, A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30089-9 · Cited by 472
Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
Molina, J.-M., Charreau, I., Chidiac, C., Pialoux, G., Cua, E., Delaugerre, C., Capitant, C., Rojas-Castro, D., Fonsart, J., Bercot, B., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30725-9 · Cited by 449
Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis.
Traeger, M. W., Schroeder, S. E., Wright, E. J., Hellard, M. E., Cornelisse, V. J., Doyle, J. S., & Stoové, M. A. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy182 · Cited by 447
Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review
Mayer, K. H., Agwu, A. L., & Malebranche, D. J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01295-0 · Cited by 438
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER) primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Mayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31065-5 · Cited by 428
Self-citation
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
Klatt, N. R., Cheu, R., Birse, K., Zevin, A. S., Perner, M., Noël-Romas, L., Grobler, A., Westmacott, G., Xie, I. Y., Butler, J., et al. (2017) · Science · doi:10.1126/science.aai9383 · Cited by 428
Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection
Traeger, M. W., Cornelisse, V. J., Asselin, J., Price, B., Roth, N. J., Willcox, J., Tee, B. K., Fairley, C. K., Chang, C. C., Armishaw, J., et al. (2019) · JAMA · doi:10.1001/jama.2019.2947 · Cited by 427
The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States
Siegler, A. J., Mouhanna, F., Mera, R. M., Weiss, K. M., Pembleton, E. S., Guest, J. L., Jones, J. S., Castel, A. D., Yeung, H., Kramer, M. R., et al. (2018) · Annals of Epidemiology · doi:10.1016/j.annepidem.2018.06.005 · Cited by 413
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Baeten, J. M., Palanee‐Phillips, T., Brown, E. R., Schwartz, K. D., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Kiweewa, F. M., Nair, G., Mhlanga, F., et al. (2016) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000489577.60775.40 · Cited by 373
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study
Grulich, A. E., Guy, R., Amin, J., Jin, F., Selvey, C., Holden, J., Schmidt, H.-M. A., Zablotska, I., Price, K., Whittaker, B., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30215-7 · Cited by 381
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., et al. (2019) · JAMA · doi:10.1001/jama.2019.6390 · Cited by 312
PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists
Petroll, A. E., Walsh, J. L., Owczarzak, J., McAuliffe, T. L., Bogart, L. M., & Kelly, J. A. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1625-1 · Cited by 314
HIV
Ghosn, J., Taiwo, B., Seedat, S., Autran, B., & Katlama, C. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31311-4 · Cited by 332
Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation
Marcus, J. L., Hurley, L. B., Hare, C. B., Nguyen, D. P., Phengrasamy, T., Silverberg, M. J., Stoltey, J. E., & Volk, J. E. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001129 · Cited by 290
Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations
Murchú, É. Ó., Marshall, L., Hayes, C., Harrington, P., Moran, P., Teljeur, C., & Ryan, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2020-048478 · Cited by 294
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM
Hosek, S., Rudy, B. J., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rutledge, B. N., Liu, N., Brothers, J., Mulligan, K. M., Zimet, G. D., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001179 · Cited by 275
Self-citation
Preexposure Prophylaxis for the Prevention of HIV Infection
Chou, R., Evans, C., Hoverman, A. S., Sun, C. J., Dana, T., Bougatsos, C., Grusing, S., & Korthuis, P. T. (2019) · JAMA · doi:10.1001/jama.2019.2591 · Cited by 275
HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery
Celum, C., Delany‐Moretlwe, S., Baeten, J. M., van der Straten, A., Hosek, S., Bukusi, E. A., McConnell, M. A., Barnabas, R. V., & Bekker, L. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25298 · Cited by 265
HIV Preexposure Prophylaxis
Riddell, J., Amico, K. R., & Mayer, K. H. (2018) · JAMA · doi:10.1001/jama.2018.1917 · Cited by 265
Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review
Pleuhs, B., Quinn, K. G., Walsh, J. L., Petroll, A. E., & John, S. A. (2020) · AIDS Patient Care and STDs · doi:10.1089/apc.2019.0189 · Cited by 260
A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?
Sidebottom, D. B., Ekström, A. M., & Strömdahl, S. K. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3463-4 · Cited by 258
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis
Zhang, J., Li, C., Xu, J., Hu, Z., Rutstein, S. E., Tucker, J. D., Ong, J. J., Jiang, Y., Geng, W., Wright, S. T., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00030-3 · Cited by 238
Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men
Eaton, L. A., Kalichman, S. C., Price, D. M., Finneran, S. D., Allen, A. M., & Maksut, J. L. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1690-0 · Cited by 234
Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study.
Jenness, S. M., Weiss, K. M., Goodreau, S. M., Gift, T., Chesson, H., Hoover, K. W., Smith, D. K., Liu, A. Y., Sullivan, P. S., & Rosenberg, E. S. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix439 · Cited by 224
The global response to HIV in men who have sex with men
Beyrer, C., Baral, S., Collins, C., Richardson, E. T., Sullivan, P. S., Sánchez, J., Trapence, G., Katabira, E., Kazatchkine, M. D., Ryan, O., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30781-4 · Cited by 223
Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis
Tan, D. H. S., Hull, M., Yoong, D., Tremblay, C. L., O’Byrne, P., Thomas, R., Kille, J., Baril, J.-G., Cox, J., Giguère, P., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170494 · Cited by 221
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States
Hosek, S., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rudy, B. J., Rutledge, B. N., Liu, N., Harris, D. R., Mulligan, K. M., Zimet, G. D., et al. (2017) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2017.2007 · Cited by 223
Self-citation
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Markowitz, M. H., Frank, I., Grant, R. M., Mayer, K. H., Elion, R., Goldstein, D. A., Fisher, C., Sobieszczyk, M. E., Gallant, J. E., Tieu, H., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30068-1 · Cited by 217
The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study
Velloza, J., Khoza, N., Scorgie, F., Chitukuta, M., Mutero, P., Mutiti, K. S., Mangxilana, N. T., Nobula, L., Bulterys, M. A., Atujuna, M., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25463 · Cited by 225
Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics
Sewell, J., Miltz, A. R., Lampe, F. C., Cambiano, V., Speakman, A., Phillips, A. N., Stuart, D., Gilson, R. J. C., Asboe, D., Nwokolo, N. C., et al. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.01.001 · Cited by 214
Self-citation
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
Baeten, J. M., Heffron, R. A., Kidoguchi, L., Mugo, N., Katabira, E. T., Bukusi, E. A., Asiimwe, S. B., Haberer, J. E., Morton, J. F., Ngure, K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002099 · Cited by 217
Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017
Sullivan, P. S., Mera, R. M., Mouhanna, F., Pembleton, E. S., Guest, J. L., Jones, J. S., Castel, A. D., Yeung, H., Kramer, M. R., McCallister, S. H., et al. (2018) · Annals of Epidemiology · doi:10.1016/j.annepidem.2018.06.009 · Cited by 218
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study
Grinsztejn, B. G. J., Hoagland, B., Moreira, R. I., Kallas, E. G., Madruga, J. V., Goulart, S. P., Leite, I. C., de Freitas, L. A., Martins, L. M. R., Torres, T. S., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30008-0 · Cited by 221
Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men
Kojima, N., Davey, D. J., & Klausner, J. D. (2016) · AIDS · doi:10.1097/qad.0000000000001185 · Cited by 194
Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States
Jenness, S. M., Goodreau, S. M., Rosenberg, E. S., Beylerian, E. N., Hoover, K. W., Smith, D. K., & Sullivan, P. S. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw223 · Cited by 203
Increasing awareness of HIV pre‐exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and meta‐analysis of global data
Sun, Z., Gu, Q., Dai, Y., Zou, H., Agins, B., Chen, Q., Li, P., Shen, J., Yang, Y., & Jiang, H. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25883 · Cited by 199
A Global Estimate of the Acceptability of Pre-exposure Prophylaxis for HIV Among Men Who have Sex with Men: A Systematic Review and Meta-analysis
Peng, P., Su, S., Fairley, C. K., Chu, M., Jiang, S., Zhuang, X., & Zhang, L. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1675-z · Cited by 191
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
Landovitz, R. J., Li, S., Eron, J. J., Grinsztejn, B. G. J., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L. M., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30106-5 · Cited by 186
Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17
Holt, M., Lea, T., Mao, L., Kolstee, J., Zablotska, I., Duck, T., Allan, B., West, M., Lee, E., Hull, P., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30072-9 · Cited by 182
STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany
MSM Screening Study group, Jansen, K., Steffen, G., Potthoff, A. V., Schuppe, A.-K., Beer, D. T., Jessen, H. K., Scholten, S., Spornraft‐Ragaller, P., Bremer, V., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4831-4 · Cited by 196
Awareness and willingness to use HIV pre‐exposure prophylaxis among men who have sex with men in low‐ and middle‐income countries: a systematic review and meta‐analysis
Yi, S., Tuot, S., Mwai, G. W., Ngin, C., Chhim, K., Pal, K., Igbinedion, E., Holland, P., Choub, S. C., & Mburu, G. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21580 · Cited by 183
Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis
Ong, J. J., Baggaley, R. C., Wi, T. E., Tucker, J. D., Fu, H., Smith, M. K., Rafael, S., Anglade, V., Falconer, J., Ofori-Asenso, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17134 · Cited by 173
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Landovitz, R. J., Li, S., Grinsztejn, B. G. J., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L. M., Chau, G., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002690 · Cited by 184
Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study
Hoornenborg, E., Coyer, L., Achterbergh, R., Matser, A. A., van der Loeff, M. F. S., Boyd, A. C., van Duijnhoven, Y. T. H. P., Bruisten, S. M., Oostvogel, P. M., Davidovich, U., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30136-5 · Cited by 168
Control and prevention of infectious diseases from a One Health perspective
Ellwanger, J. H., da Veiga, A. B. G., Kaminski, V. D. L., Valverde-Villegas, J. M., de Freitas, A. W. Q., & Chies, J. A. B. (2021) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2020-0256 · Cited by 200
HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project
Eakle, R., Gomez, G. B., Naicker, N., Bothma, R., Mbogua, J., Escobar, M. A. C., Saayman, E., Moorhouse, M. A., Venter, F., Rees, H., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002444 · Cited by 162
A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians
Blackstock, O. J., Moore, B. A., Berkenblit, G. V., Calabrese, S. K., Cunningham, C. O., Fiellin, D. A., Patel, V. V., Phillips, K. A., Tetrault, J. M., Shah, M. P., et al. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3903-z · Cited by 161
Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV
Nguyen, V., Greenwald, Z. R., Trottier, H., Cadieux, M., Goyette, A., Beauchemin, M., Charest, L., Longpré, D., Lavoie, S., Tossa, H. G., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001718 · Cited by 167
Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting.
Montaño, M. A., Dombrowski, J. C., Dasgupta, S., Golden, M. R., Duerr, A., Manhart, L. E., Barbee, L. A., & Khosropour, C. M. (2019) · AIDS and Behavior · doi:10.1007/s10461-018-2252-9 · Cited by 155
Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy
Cohen, M. S., & Chen, J. S. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25355 · Cited by 178
National trends in HIV pre‐exposure prophylaxis awareness, willingness and use among United States men who have sex with men recruited online, 2013 through 2017
Sullivan, P. S., Sanchez, T., Zlotorzynska, M., Chandler, C. J., Sineath, R. C., Kahle, E., & Tregear, S. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25461 · Cited by 153
Interventions to strengthen the HIV prevention cascade: a systematic review of reviews
Krishnaratne, S., Hensen, B., Cordes, J. L., Enstone, J. E., & Hargreaves, J. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30038-8 · Cited by 160
Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study
Liu, A., Vittinghoff, E., von Felten, P., Amico, K. R., Anderson, P. L., Lester, R. T., Andrew, E. V. W., Estes, I., Serrano, P. A., Brothers, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy810 · Cited by 157
Redefining Prevention and Care: A Status-Neutral Approach to HIV
Myers, J. E., Braunstein, S., Xia, Q., Scanlin, K., Edelstein, Z. R., Harriman, G., Tsoi, B. W., Andaluz, A., Yu, E., & Daskalakis, D. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy097 · Cited by 144
Usability and Acceptability of a Mobile Comprehensive HIV Prevention App for Men Who Have Sex With Men: A Pilot Study
Sullivan, P. S., Driggers, R. A., Stekler, J. D., Siegler, A. J., Goldenberg, T., McDougal, S. J., Caucutt, J., Jones, J. S., & Stephenson, R. B. (2017) · JMIR mhealth and uhealth · doi:10.2196/mhealth.7199 · Cited by 146
Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color
Wood, S. M., Gross, R., Shea, J. A., Bauermeister, J. A., Franklin, J., Petsis, D. T., Swyryn, M., Lalley-Chareczko, L., Koenig, H. C., & Dowshen, N. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02502-y · Cited by 145
Geographic Access to Preexposure Prophylaxis Clinics Among Men Who Have Sex With Men in the United States
Siegler, A. J., Bratcher, A. M., & Weiss, K. M. (2019) · American Journal of Public Health · doi:10.2105/ajph.2019.305172 · Cited by 146
Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
McKinnon, L. R., Liebenberg, L. J. P., Yende‐Zuma, N., Archary, D., Ngcapu, S., Sivro, A., Nagelkerke, N. J. D., Garcia-Lerma, J. G., Kashuba, A. D. M., Masson, L., et al. (2018) · Nature Medicine · doi:10.1038/nm.4506 · Cited by 152
Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics
Pakianathan, M., William, W., Lee, M. J., Avery, J., Green, S., Nathan, B., & Hegazi, A. (2018) · HIV Medicine · doi:10.1111/hiv.12629 · Cited by 142
Reflections on 40 Years of AIDS
Cock, K. M. D., Jaffe, H. W., & Curran, J. W. (2021) · Emerging infectious diseases · doi:10.3201/eid2706.210284 · Cited by 154
High pre‐exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project
Hoagland, B., Moreira, R. I., Boni, R. B. D., Kallas, E. G., Madruga, J. V., Vasconcelos, R. D. P., Goulart, S. P., Torres, T. S., Marins, L. M. S., Anderson, P. L., et al. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21472 · Cited by 142
Gender-based violence and engagement in biomedical HIV prevention, care and treatment: a scoping review
Leddy, A. M., Weiss, E., Yam, E., & Pulerwitz, J. (2019) · BMC Public Health · doi:10.1186/s12889-019-7192-4 · Cited by 140
Pre-exposure Prophylaxis Uptake and Discontinuation Among Young Black Men Who Have Sex With Men in Atlanta, Georgia: A Prospective Cohort Study
Serota, D. P., Rosenberg, E. S., Sullivan, P. S., Thorne, A. L., Rolle, C.-P., del Rı́o, C., Cutro, S. R., Luisi, N., Siegler, A. J., Sanchez, T., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz894 · Cited by 135
MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.
Hoornenborg, E., Achterbergh, R. C. A., Schim van der Loeff, M. F., Davidovich, U., Hogewoning, A., de Vries, H. J. C., Schinkel, J., Prins, M., & van de Laar, T. J. W. (2017) · AIDS · doi:10.1097/qad.0000000000001522 · Cited by 137
Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study
Storholm, E. D., Volk, J. E., Marcus, J. L., Silverberg, M. J., & Satre, D. D. (2017) · Prevention Science · doi:10.1007/s11121-017-0799-8 · Cited by 147
Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand
Phanuphak, N., Sungsing, T., Jantarapakde, J., Pengnonyang, S., Trachunthong, D., Mingkwanrungruang, P., Sirisakyot, W., Phiayura, P., Seekaew, P., Panpet, P., et al. (2018) · Sexual Health · doi:10.1071/sh18065 · Cited by 138
Environmental fate and ecotoxicological effects of antiretrovirals: A current global status and future perspectives
Ncube, S., Madikizela, L. M., Chimuka, L., & Nindi, M. M. (2018) · Water Research · doi:10.1016/j.watres.2018.08.017 · Cited by 135
HIV epidemiology, prevention, treatment, and implementation strategies for public health
Mody, A., Sohn, A. H., Iwuji, C. C., Tan, R. K. J., Venter, F., & Geng, E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01381-8 · Cited by 150
Acceptability and use of a dapivirine vaginal ring in a phase III trial
Montgomery, E., van der Straten, A., Chitukuta, M., Reddy, K., Woeber, K., Atujuna, M., Bekker, L., Etima, J., Nakyanzi, T., Mayo, A., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001452 · Cited by 137
Exploring Patterns of Awareness and Use of HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men
Strauss, B. B., Greene, G. J., Phillips, G., Bhatia, R., Madkins, K., Parsons, J. T., & Mustanski, B. S. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1480-0 · Cited by 137
Recent advances in pre-exposure prophylaxis for HIV
Desai, M., Field, N. M., Grant, R. M., & McCormack, S. (2017) · BMJ · doi:10.1136/bmj.j5011 · Cited by 136
Self-citation
Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men
Greene, G. J., Swann, G., Fought, A. J., Carballo‐Diéguez, A., Hope, T. J., Kiser, P. F., Mustanski, B. S., & D’Aquila, R. T. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1565-9 · Cited by 127
Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM
Rolle, C.-P., Rosenberg, E. S., Siegler, A. J., Sanchez, T., Luisi, N., Weiss, K. M., Cutro, S. R., del Rı́o, C., Sullivan, P. S., & Kelley, C. F. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001497 · Cited by 131
Persistence on HIV preexposure prophylaxis medication over a 2‐year period among a national sample of 7148 PrEP users, United States, 2015 to 2017
Coy, K. C., Hazen, R. J., Kirkham, H. S., Delpino, A., & Siegler, A. J. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25252 · Cited by 132
Applying the Information–Motivation–Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men
Walsh, J. L. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2371-3 · Cited by 126
Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming
Hillis, A., Germain, J., Hope, V. D., McVeigh, J., & Hout, M. C. V. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-02855-9 · Cited by 136
Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access Among African American Men, Women, and MSM in the Deep South
Elopre, L. E., Kudroff, K., Westfall, A. O., Overton, E. T., & Mugavero, M. J. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001165 · Cited by 127
Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation
Cambiano, V., Miners, A. H., Dunn, D. T., McCormack, S., Ong, K. J., Gill, O. N., Nardone, A., Desai, M., Field, N. M., Hart, G., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30540-6 · Cited by 123
Self-citation
Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection – A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis
Werner, R. N., Gaskins, M. D., Nast, A., & Dressler, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208107 · Cited by 118
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
Stephenson, K. E., Wagh, K., Korber, B., & Barouch, D. H. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-080219-023629 · Cited by 118
Sources of HIV infection among men having sex with men and implications for prevention
Ratmann, O., van Sighem, A., Bezemer, D., Gavryushkina, A. “., Jurriaans, S., Wensing, A. M. J., de Wolf, F., Reiss, P., Fraser, C., & cohort, A. O. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad1863 · Cited by 116
Geographic and Individual Associations with PrEP Stigma: Results from the RADAR Cohort of Diverse Young Men Who have Sex with Men and Transgender Women
Mustanski, B. S., Ryan, D. T., Hayford, C. S., Phillips, G., Newcomb, M. E., & Smith, J. D. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2159-5 · Cited by 115
Daily and event‐driven pre‐exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence
Vuylsteke, B., Reyniers, T., Baetselier, I. D., Nöstlinger, C., Crucitti, T., Buyze, J., Kenyon, C. R., Wouters, K., & Laga, M. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25407 · Cited by 112
Long-Acting HIV Drugs for Treatment and Prevention
Gulick, R. M., & Flexner, C. W. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-013717 · Cited by 119
Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care
Krakower, D., Maloney, K. M., Powell, V. E., Levine, K., Grasso, C., Melbourne, K., Marcus, J. L., & Mayer, K. H. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25250 · Cited by 114
The preexposure prophylaxis revolution; from clinical trials to programmatic implementation
Mugo, N., Ngure, K., Kiragu, M., Irungu, E., & Kilonzo, N. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000224 · Cited by 118
Expert consensus statement on the science of HIV in the context of criminal law
Barré‐Sinoussi, F., Karim, S. S. A., Albert, J., Bekker, L., Beyrer, C., Cahn, P. E., Calmy, A., Grinsztejn, B. G. J., Grulich, A. E., Kamarulzaman, A., et al. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25161 · Cited by 124
The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
Donnell, D. J., Ramos, E. M., Celum, C., Baeten, J. M., Dragavon, J., Tappero, J. W., Lingappa, J. R., Ronald, A., Fife, K. H., & Coombs, R. W. (2017) · AIDS · doi:10.1097/qad.0000000000001577 · Cited by 113
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial
Bekker, L., Roux, S., Sebastien, E., Yola, N., Amico, K. R., Hughes, J. P., Marzinke, M. A., Hendrix, C. W., Anderson, P. L., Elharrar, V., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30156-x · Cited by 119
Self-citation
Disclosure of Same-Sex Behaviors to Health-care Providers and Uptake of HIV Testing for Men Who Have Sex With Men: A Systematic Review
Qiao, S., Zhou, G., & Li, X. (2018) · American Journal of Men s Health · doi:10.1177/1557988318784149 · Cited by 112
Da evidência à ação: desafios do Sistema Único de Saúde para ofertar a profilaxia pré-exposição sexual (PrEP) ao HIV às pessoas em maior vulnerabilidade
Zucchi, E. M., Grangeiro, A., Ferraz, D., Pinheiro, T. F., Alencar, T., Ferguson, L., Estevam, D. L., & Munhoz, R. (2018) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00206617 · Cited by 130
Pre-Exposure Prophylaxis (PrEP) Use and Condomless Anal Sex: Evidence of Risk Compensation in a Cohort of Young Men Who Have Sex with Men
Newcomb, M. E., Moran, K., Feinstein, B. A., Forscher, E. C., & Mustanski, B. S. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001604 · Cited by 114

Authors: McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., Mackie, N., Bowman, C., Lacey, C. J., Apea, V., Brady, M., Fox, J., Taylor, S., Antonucci, S., Khoo, S. H., Rooney, J., Nardone, A., Fisher, M., McOwan, A., Phillips, A. N., Johnson, A. M., Gazzard, B., & Gill, O. N.
Affiliations: Chelsea and Westminster Hospital NHS Foundation Trust (GB)
MRC Clinical Trials Unit at UCL (GB)
Public Health England (GB)
Central and North West London NHS Foundation Trust (GB)
Royal Sussex County Hospital (GB)
Homerton University Hospital NHS Foundation Trust (GB)
Imperial College Healthcare NHS Trust (GB)
Sheffield Teaching Hospitals NHS Foundation Trust (GB)
University of York (GB)
Barts Health NHS Trust (GB)
King's College Hospital NHS Foundation Trust (GB)
Guy's and St Thomas' NHS Foundation Trust (GB)
Heart of England NHS Foundation Trust (GB)
University of Liverpool (GB)
Gilead Sciences (United States) (US)
University College London (GB)
Corresponding author: McCormack, Sheena
ORCID: McCormack, Sheena
Dunn, David T
Desai, Monica
Dolling, David I
Gafos, Mitzy
Gilson, Richard
Sullivan, Ann K
Clarke, Amanda
Lacey, Charles J
Apea, Vanessa
Brady, Michael
Fox, Julie
Taylor, Stephen
Khoo, Saye H
Rooney, James
Nardone, Anthony
Fisher, Martin
Phillips, Andrew N
Gill, Owen N
Venue: The Lancet
Publisher: Elsevier BV
Published: 2016-01
Volume: 387
Issue: 10013
Pages: 53-60
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(15)00056-2
PMC: PMC4700047
OpenAlex: W1413161224
Cited by: 1,878
References: 24
Citations by year: 2026: 61 · 2025: 122 · 2024: 136 · 2023: 163 · 2022: 174 · 2021: 201 · 2020: 181 · 2019: 240 · 2018: 207 · 2017: 213 · 2016: 152
FWCI: 154.11
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: The Lancet (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: National Institute for Health and Care Research (ACF-2008-20-002, NF-SI-0508-10244)
Public Health England
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords: tenofovir disoproxil fumarate, emtricitabine, risk compensation, men who have sex with men, post-exposure prophylaxis, trial retention, PrEP adherence, sexual health clinics
MeSH terms: Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Adult, Bisexuality, England, Humans, Male, Pilot Projects, HIV-1, HIV Infections, Treatment Outcome, Condoms, Homosexuality, Male, Anti-HIV Agents, Unsafe Sex, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks